Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 3;3(11):e00429.
doi: 10.1016/j.heliyon.2017.e00429. eCollection 2017 Nov.

Combined use of electroconvulsive therapy and antipsychotics (both clozapine and non-clozapine) in treatment resistant schizophrenia: A comparative meta-analysis

Saeed Ahmed  1 , Ali Mahmood Khan  2 , Hema Madhuri Mekala  3 , Hema Venigalla  4 , Rizwan Ahmed  5 , Amira Etman  6 , Michael Esang  1 , Mustafa Qureshi  7
Affiliations

Combined use of electroconvulsive therapy and antipsychotics (both clozapine and non-clozapine) in treatment resistant schizophrenia: A comparative meta-analysis

Saeed Ahmed et al. Heliyon. .

Abstract

Aim: To assess the relative efficacies of clozapine plus Electroconvulsive Therapy (ECT) compared against non-clozapine typical and atypical antipsychotics plus ECT for the treatment of "Treatment Resistant Schizophrenia" (TRS). Primarily to assess if clozapine delivers a significant improvement over other antipsychotics when combined with ECT.

Design: Major electronic databases were searched between 1990 and March 2017 for trials measuring the effects of either clozapine augmented ECT, other antipsychotic-augmented ECT, or both. After the systematic review of the data, a random-effects meta-analysis was conducted measuring the relative effect sizes of the different treatment regimens.

Subjects: 1179 patients in 23 studies reporting the usage of ECT augmentation with antipsychotics. A total of 95 patients were tested with clozapine, and ECT (9 studies) and 1084 patients were tested with non-clozapine antipsychotics (14 studies) such as flupenthixol, chlorpromazine, risperidone, sulpiride, olanzapine, and loxapine with concurrent ECT treatment considered for systematic review. Of these, 13 studies reported pre and post-treatment scores were included in the meta-analysis.

Main outcome measures: The main outcome measure was the presence and degree of both positive and negative psychotic symptoms, as measured by either of two standardized clinician administered tests, the Brief Psychiatric Rating Scale (BPRS), and the Positive and Negative Symptom Scale (PANSS).

Results: The comparison of the different antipsychotics established the supremacy of ECT-augmented clozapine treatment against other typical and atypical antipsychotics. The Forest Plot revealed that the overall standard mean difference was 0.891 for non-clozapine studies and 1.504 for clozapine studies, at a 95% interval. Furthermore, the heterogeneity plots showed that while clozapine studies showed no significant heterogeneity, non-clozapine studies showed an I2 statistic value at 42.19%, suggesting moderate heterogeneity. Lastly, publication bias showed asymmetrical plots and significant values of Kendal's tau and Egger's rank test.

Conclusion: ECT augmentation technique was found to be effective in the reduction of psychometric scale scores, and the resulting improvement was significant. Clozapine maintained its stance as the most effective treatment for Treatment-Resistant Schizophrenia, followed by flupenthixol.

Keywords: Evidence-based medicine; Psychiatry.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Literature search and selection flow chart of studies included.
Fig. 2
Fig. 2
Forest plot for (a) Non Clozapine plus ECT and (b) Clozapine plus ECT treatment efficacies respectively.
Fig. 3
Fig. 3
Funnel plot for Publication bias in Non-Clozapine group of studies.
Fig. 4
Fig. 4
Funnel Plot for Publication Bias in Clozapine group of studies.
See this image and copyright information in PMC

References

    1. Patel K.R., Cherian J., Gohil K., Atkinson D. Schizophrenia overview and treatment options. Pharmacy and Therapeutics. 2014;39(9):638. - PMC - PubMed
    1. Meltzer H.Y. Clozapine balancing safety with superior antipsychotic efficacy. Clin. Schizophr. Relat. Psychoses. 2012;6(3):134–144. - PubMed
    1. Joober R., Boksa P. Clozapine a distinct, poorly understood and under-used molecule. J. Psychiatry Neurosci. 2010;35(3):147. - PMC - PubMed
    1. Elkis H. Therapy-Resistant Schizophrenia. Karger Publishers; 2010. History and current definitions of treatment-resistant schizophrenia; pp. 1–8. Vol. 26.
    1. Englisch S., Zink M. Treatment-resistant schizophrenia: evidence-based strategies. Mens Sana Monogr. 2012;10(1):20. - PMC - PubMed

LinkOut - more resources